Delivery Order SPE2DB20D1109-SPE2DB21FP95J

Award Date 9/7/21
Potential Completion Date 9/8/21
Potential Value $30K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $7,918.17 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
This federal contract award, valued at $23,835.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Xifaxan 550 mg tablets. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for the company to provide...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $1,322.83 firm fixed-price delivery order falls under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business as Amerisourcebergen) and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,596.05 delivery order covers the supply of the medication Xifaxan 550 mg tablets. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc., which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,406.52 delivery order is for the supply of Xifaxan 550 mg tablets. The contract is a firm fixed-price Delivery Order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen's parent company, Cencora, Inc. This IDC, valued at up to $999,999,999.00, serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company, for the delivery of Xifaxan 550 mg tablets. The contract has an award value of $5,305.54 and an ultimate completion date of January 12, 2022. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,666.94 firm fixed-price delivery order is for the supply of Xifaxan 550 mg tablets, a specialty medication. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
This federal contract award, with ID SPE2DB22D2206|SPE2DB24FFD60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $125,365.21 firm-fixed-price delivery order is for the supply of Xifaxan 550 mg tablets. This award is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of Xifaxan 550 mg tablets. The contract has a ceiling value of $85,162.48 and a completion date of May 3, 2024. This is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2025. The...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB21FP95J
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $29,616.91 firm-fixed price delivery order was placed against an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., which has a ceiling value of $999,999,999.00 and runs through November 2026. This single-award IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract award did not have a set-aside designation, indicating full and open competition. AmerisourceBergen's extensive pharmaceutical distribution capabilities and existing contracting relationships with the DLA and other federal agencies position the company as a critical vendor for meeting the government's essential healthcare needs.

Generated 2/27/25, 1:17 PM